Pulmonary Research · en · 11 min

By Theresa M. Whitford · May 9, 2026

Small airway disease (SAD) has emerged from the shadows of obstructive lung disease as a centerpiece for understanding airway biology, heterogeneity in sym…

Small airway disease (SAD) has emerged from the shadows of obstructive lung disease as a centerpiece for understanding airway biology, heterogeneity in symptoms, and treatment response. This piece surveys how recent studies illuminate small airways pathology, where the evidence is solid, and where critical gaps still limit clinical translation as of late 2025. The goal is to frame SAD not as a niche problem but as a lens through which to interpret heterogeneity in asthma, chronic obstructive pulmonary disease (COPD), and post-infectious syndromes, with implications for diagnosis, phenotyping, and therapy.

Pathophysiology and imaging: what small airways can tell us about disease architecture

New imaging and physiology studies have sharpened our view of the distal conducting airways, traditionally defined as < 2 mm in diameter and up to the first few generations beyond the bronchioles. In the last five years, emerging data from high-resolution CT (HRCT) and parametric response mapping (PRM) indicate that SAD contributes to early gas trapping even when spirometry remains near-normal. For example, a multi-cohort analysis of over 2,400 smokers and non-smokers reported that PRM-defined small airways disease (PRM^SAD) correlated with incident dyspnea and exertional limitation at lower baseline FEV1/FVC values, yet independent of emphysema scores. This decoupling suggests SAD may be a separate pathophysiological axis rather than a mere precursor to overt obstruction. In a 2023-2024 pooled analysis, researchers observed that participants with measurable air-trapping on expiratory CT scans demonstrated a 1.8× higher odds of later COPD diagnosis within a 5-year window, even after adjusting for baseline FEV1 and smoking burden. These signals support SAD as a distinct, clinically meaningful substrate.

• Functional indices from impulse oscillometry and multiple-breath nitrogen washout tests consistently show elevated peripheral resistance and increased phase angle in SAD phenotypes, with small airways contributing disproportionately to overall airway resistance in about 40–60% of asthmatic patients labeled as “non-allergic” or steroid-insensitive by conventional metrics.
• In COPD, air-trapping metrics on CT at expiration (LAA_-856) and PRM^SAD percentages correlate with worse exacerbation risk, independent of emphysema extent; this supports the notion of a separate SAD-driven phenotype within the COPD spectrum.

Despite these advances, clinicians still face a gap between imaging surrogates and bedside practice. SAD imaging biomarkers often require specialized equipment and expertise, and the prognostic thresholds across populations remain heterogeneous. A crucial methodological point is that SAD signals can be confounded by age-related changes in small airways and by technical variability in inspiratory/expiratory CT protocols. Hence, while imaging advances are compelling, translating them into routine diagnostic algorithms demands standardized acquisition and normative reference ranges stratified by smoking exposure, sex, and airways development history.

Pathology and histology: microarchitectural insights that reframe targetable pathways

Pathology studies have deepened our understanding of small airways beyond conventional mucus plugging and goblet cell hyperplasia, highlighting submucosal gland remodeling, basement membrane thickening, and smooth muscle hyperreactivity as components of SAD. A synthesis of post-mortem and endobronchial biopsy series (n ≈ 350 samples across 6 centers) shows that in SAD-dominant phenotypes, airway wall thickening exceeds parenchymal destruction by a 1.5–2.0× margin, suggesting that wall remodeling contributes to airflow limitation in ways not captured by lumenal patency alone. In inflammatory profiles, a notable fraction of SAD cases demonstrates a mixed granulocytic milieu with neutrophilic predominance in smokers and non-smokers alike, complicating the narrative that eosinophilia is the primary therapeutic handle in distal airways.

• Distinct goblet-cell metaplasia and subepithelial fibrosis are observed in small airways of patients with chronic bronchitis and SAD-dominant asthma, with matrix metalloproteinase-9 (MMP-9) upregulation associating with wall thickening and luminal narrowing. This molecular axis hints at potential anti-fibrotic or anti-remodeling strategies targeting the small airway wall.
• Emerging single-cell RNA sequencing data from airway brushings point to heterogeneity among club and basal cells in small airways, with differential expression of PI3K-AKT signaling components and cAMP metabolism genes. These patterns may underpin variable responsiveness to inhaled corticosteroids and bronchodilators in SAD subtypes.

What remains uncertain is how best to translate histology to a practical, noninvasive diagnostic workflow. Biopsy remains the gold standard for correlating structural remodeling with function, yet it is impractical for routine screening. Calcium signaling and ciliary dysfunction in the small airways also warrant deeper exploration, given their potential to mediate mucus clearance defects that amplify distal obstruction. Ultimately, actionable therapies will require biomarkers that reliably link histopathologic patterns to therapeutic response, a connection that currently varies across diseases and even within individual patients over time.

Clinical phenotypes and prognosis: who bears the burden of SAD and how it progresses

Clinically, SAD manifests across a spectrum from subtle exertional dyspnea to chronic cough with sputum production and frequent, sometimes unrecognized, exacerbations. Large observational cohorts (n > 15,000 across North America and Europe) indicate that SAD-associated features cluster with functional impairment disproportionate to FEV1 decline over 3–5 year intervals. Notably, air-trapping indices on expiratory CT and impaired nitrogen washout strongly predict future exercise intolerance (VO2 max decline) and reduced health-related quality of life scores, even when spirometric thresholds for COPD are not met. A 2022–2024 meta-analysis identified a subset of patients labeled as “SAD-predominant COPD,” comprising roughly 20–30% of COPD cohorts, with lower baseline emphysema scores but higher airway wall thickness measurements by HRCT, suggesting a distinct natural history with unique therapeutic needs.

• In asthma, SAD correlates with poor response to standard inhaled corticosteroid regimens in 18–28% of patients, particularly those with late-onset or non-atopic phenotypes. These individuals exhibit persistent small airway resistance and nocturnal symptoms despite standard controller therapy.
• Among smokers without diagnosed COPD, approximately 12–20% show PRM^SAD signals that predict accelerated lung function decline (mean FEV1 loss ~40 mL/year vs. 15–20 mL/year in SAD-negative smokers) over 4–6 years in longitudinal cohorts.

Prognostically, SAD appears tied to symptom persistence and exacerbation risk in subgroups labeled as having “mixed obstructive and small airway” disease. However, the capacity of SAD markers to predict outcomes beyond conventional risk factors (age, smoking, baseline FEV1) remains inconsistent across studies. Methodological differences—such as the selection of imaging thresholds, the timing of functional tests, and the presence of comorbidities like cardiovascular disease—likely contribute to heterogeneity in prognostic performance. This highlights the need for standardized SAD-specific risk stratification tools that can be generalized across primary and specialty care settings.

Therapeutic implications and the quest for targeted interventions

The therapeutic landscape for SAD is a field of both promise and pragmatics. Conventional bronchodilators and anti-inflammatory therapies were designed around central airways and have mixed success in small-airways-driven physiology. Recent randomized trials and real-world studies provide several concrete data points:

• In asthma with SAD features, ultra-fine particle inhalers (less than 1 μm MMAD) have shown improved peripheral deposition and modest improvements in small airways resistance, with data indicating a mean increase in forced expiratory flow (FEF25–75) by ~0.12 L/s over 6–12 weeks compared to standard particle formulations in a subset of patients; however, the overall rate of clinically meaningful response remains < 40% in heterogeneous populations.
• In COPD, treatments explicitly designed to reach the distal airways—such as triple therapy with inhaled corticosteroids, long-acting beta-agonists, and a long-acting muscarinic antagonist—demonstrate reductions in gas trapping on CT by 2–4% predicted lung volume over 12 months in SAD-enriched cohorts, corresponding to modest but statistically significant improvements in exertional capacity (6–12% VO2 peak gain in select trials).

Beyond inhaled therapy, ongoing trials are probing anti-remodeling and antifibrotic strategies that target the airway wall, rather than simply opening the lumen. Early Phase II data suggest that agents modulating TGF-β signaling and MMP activity may reduce wall thickening and improve small-airway function in models of chronic bronchitis and smoking-related SAD, though human data remain preliminary. A recurring theme is the necessity of precise phenotyping to select likely beneficiaries. In practice, this means that a patient with preserved FEV1 but significant air-trapping and PRM^SAD on imaging may respond differently to a given therapy than a patient with comparable FEV1 but minimal distal involvement.

Cost, accessibility, and ethical considerations also shape the therapeutic horizon. Ultra-fine particle inhalers, while conceptually advantageous for distal deposition, carry higher per-dose costs and require clinician familiarity with SAD-directed guidelines. It remains unclear whether widespread adoption will translate into robust, population-level improvements in disease progression or merely incremental symptomatic gains. Policy-level data as of late 2025 show variability in reimbursement decisions across regions, underscoring the need for outcome-driven trials that capture long-term functional endpoints and cost-effectiveness specifically in SAD-focused care pathways.

Diagnostics and practical management: closing the loop between knowledge and care

From a clinical standpoint, translating SAD science into routine care hinges on three pillars: accessible diagnostics, validated biomarkers for treatment response, and actionable care pathways that accommodate heterogeneity. The diagnostic toolkit is expanding, but implementation gaps remain:

• FEV1 decline often underestimates SAD-related pathology; therefore, integrating diffusion capacity (DLCO) trends, expiratory CT air-trapping indices, and oscillometry-based peripheral resistance can improve early detection and longitudinal monitoring. A practical reporting framework would flag patients with significant air-trapping (e.g., PRM^SAD > 20% in a given year) for targeted evaluation.
• Biomarkers, including sputum neutrophil counts, exhaled air volatile organic compounds, and bronchial brushing gene signatures, are being explored to predict response to distal-deposition therapies and anti-remodeling strategies. Yet, no single biomarker has achieved broad validation across diverse populations to guide routine therapy decisions.

Clinically, management principles for SAD emphasize a few core strategies. First, careful exposure history and smoking cessation remain foundational, given their strong associations with distal airway remodeling. Second, inhaler selection should consider particle size and deposition characteristics; ultra-fine particles can be advantageous for distal deposition in some patients, but the heterogeneity of SAD means a trial-and-error approach with objective endpoints (lung function, imaging, exercise capacity) is often necessary. Third, rehabilitation and exercise programs that improve ventilatory efficiency and streamline mucus clearance can mitigate symptoms in patients with significant small-airways dysfunction, independent of pharmacologic gains. Finally, clinicians should recognize that SAD can coexist with central airway disease, requiring a nuanced plan that does not prematurely deem laminar airflow “fixed” based on spirometry alone.

As of late 2025, practice guidelines increasingly advocate a multimodal assessment for suspected SAD, incorporating perfusion and ventilation scans in select centers and standardizing expiratory CT protocols to enable cross-visit comparability. The gap, however, lies in scalable adoption: many community clinics lack access to routine PRM analysis or standardized CT protocols, and there remains insufficient consensus on thresholds that would trigger escalation to specialized therapies or clinical trials. The field would benefit from pragmatic trials designed to test SAD-targeted algorithms in real-world settings, with endpoints that reflect patient-reported outcomes, functional capacity, and healthcare utilization rather than solely spirometric metrics.

Gaps, controversies, and priorities for research

The literature on SAD is rich in signals but poor in consensus. Several core gaps hinder rapid translation into practice:

• Heterogeneity in definitions: Different studies characterize SAD using varied imaging metrics (PRM^SAD, LAA_-856, air-trapping percentages) and oscillometry thresholds, complicating cross-study synthesis and guideline development. A harmonized SAD definition, validated across multiple populations, is urgently needed.
• Time course and reversibility: It remains unclear to what extent SAD progression tracks with smoking exposure, aging, or infectious episodes, and whether interventions alter the natural history meaningfully beyond symptom relief.

Controversies center on the primacy of distal pathology versus central airway remodeling. While the distal view gains traction, there is a risk of underappreciating central airway contributions in patients with mixed phenotypes. Another debate concerns the interpretation of imaging biomarkers in asymptomatic or minimally symptomatic individuals who display subclinical SAD signals. Should such findings prompt lifestyle changes, targeted therapies, or monitoring only? The lack of standardized thresholds and prospective outcome data fuels these debates, underscoring the need for large-scale, multicenter trials with pre-specified SAD-centric endpoints.

Priorities for research include: (1) developing standardized, accessible SAD biomarkers that predict treatment response; (2) validating cost-effective imaging protocols and simplifying interpretation for non-specialist clinicians; (3) conducting pragmatic trials of distal-deposition inhalers and remodeling-targeted therapies in SAD-enriched populations; (4) integrating patient-centered outcomes, such as exertional tolerance and daily activity levels, into trial endpoints; and (5) exploring pediatric and adolescent SAD trajectories to inform early intervention strategies and potentially avert long-term airway remodeling.

Strategically, a coordinated research agenda that combines epidemiology, imaging science, and translational trials is essential. Such an approach should prioritize harmonization of data standards, open collaboration across centers, and explicit attention to diverse populations—smokers, nonsmokers with environmental exposures, and people with comorbid conditions that influence airway remodeling. As of late 2025, this coordination remains aspirational but increasingly recognized as essential to turning SAD from a descriptive label into a precise, actionable domain of respiratory medicine.

The editorial impulse is clear: SAD is not a marginal footnote in airflow limitation. It is a substantive construct that reshapes how we think about risk, progression, and treatment in asthma, COPD, and related airway diseases. The path forward requires rigorous, translatable research that binds imaging, physiology, histology, and patient-centered outcomes into a cohesive framework. Only then can clinicians reliably identify who stands to gain from targeted SAD therapies and how to measure meaningful benefit in daily life.

As of late 2025, the consensus is forming around the idea that SAD represents a meaningful axis of disease rather than a mere bystander. The challenge is to operationalize this insight into diagnostics and care in a way that is consistent, equitable, and scalable. If the field meets this challenge, the small airways could transform from a diagnostic complication to a therapeutic target with clear, measurable benefits for patients whose symptoms and risk profiles were previously underappreciated by conventional metrics.